Asset
TALETRECTINIB
Nuvation Bio Inc. Class A Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05357820 | phase1 | completed | 2021-07-19 | 2021-12-03 | Nuvation Bio Inc. | A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK |
| NCT04395677 | phase2 | active_not_recruiting | 2020-07-07 | 2024-06-07 | Nuvation Bio Inc. | A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene |
| NCT05357911 | phase1 | completed | 2021-07-13 | 2021-08-20 | Nuvation Bio Inc. | A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin |
| NCT04617054 | phase2 | terminated | 2021-06-01 | 2024-12-06 | Nuvation Bio Inc. | Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion |
FDA applications (0)
This company has no applications containing this asset.